On August 3, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) released its annual report. Highlights from 2022-2023 include:
- Development of procedures for review of nationally procured pharmaceuticals and delivery of implementation advice for certain COVID-19 treatments.
- Reports on evidence and resources for post-COVID condition (also known as long COVID).
- Creation of new reimbursement review pathways including the Non-Sponsored Single Drug Review and Streamlined Drug Class Review and a consultation on time-limited drug reimbursement recommendations.
- Creation of the Post-Market Drug Evaluation Program.
- Release of the 2023 Watch List: Top 10 Precision Medicine Technologies and Issues.
- Start of a learning period and development of draft guidance regarding the use of real-world evidence.
- Report on a potential pan-Canadian formulary.
Related Publications & Articles
-
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Minister of Health proposes legislation for first phase of national universal pharmacare
On February 29, 2024, the Minister of Health announced the introduction of Bill C-64, An Act respecting pharmacare (Pharmacare Act).Read More -
PMPRB releases 2022 Annual Report and March 2024 NEWSletter
On February 16, 2024, the Minister of Health tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB).Read More